melanoma
MELANOMA
Melanoma is a skin neoplasm that originates from malignant transformation of melanocytes.
It commonly occurs in the extremities of women and on trunk or head and neck in men.
Metastases are via lymphatic and hematogenous routes.
  1. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011 Nov;65(5):1032-1047. http://pic2.cmt.com.cn/WebImages/Res/20130528/20130528_777961e9-aab4-432d-9349-860041357fe1.pdf. Accessed 19 Dec 2013. PMID: 21868127
  2. Coit DG, Andtbacka R, Anker CJ et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:395-407. http://www.jnccn.org/content/11/4/395.full.pdf. Accessed 08 Jan 2014. PMID: 23584343
  3. Dummer R, Guggenheim M, Arnold AW, et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2011 Dec;141:w13320. doi: 10.4414/smw.2011.13320. Accessed 19 Dec 2013. PMID: 22180245
  4. Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii86-vii91. http://annonc.oxfordjournals.org/content/23/suppl_7/vii86.full.pdf+html. Accessed 19 Dec 2013. PMID: 22997461
  5. European Society for Medical Oncology. FDA approves pembrolizumab for advanced melanoma. ESMO. http://www.esmo.org/Oncology-News/FDA-Approves-Pembrolizumab-for-Advanced-Melanoma. 05 Sep 2014. Accessed 09 Sep 2014.
  6. Fuerst M. Metastatic melanoma: immunotherapy with pembrolizumab induces durable responses. Oncology Times. 2014 Jul;36(13):35-36. doi: 10.1097/01.COT.0000452086.09862.55. Accessed 09 Sep 2014.
  7. Melanoma. Medicines Complete. http://www.medicinescomplete.com/mc/martindale/current/1800-a4-737-j.htm#m1800-a4-814-h . 20 Aug 2010. Accessed 06 Jan 2014.
  8. National Cancer Institute: PDQ® Melanoma Treatment. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page9/AllPages/Print. 11 Jul 2014. Accessed 01 Sep 2014.
  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma. Version 4.2014. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed 28 Aug 2014.
  10. Shenenberger DW. Cutaneous malignant melanoma: a primary care perspective. Am Fam Physician. 2012 Jan;85(2):161-168. http://www.aafp.org/afp/2012/0115/p161.html. Accessed 19 Dec 2013. PMID: 22335216
  11. Sosman JA. Melanoma treatment; advanced or metastatic melanoma (beyond the basics). UpToDate. http://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics. 30 May 2013. Accessed 19 Dec 2013.
  12. Tan WW. Malignant melanoma treatment protocols. Medscape. http://emedicine.medscape.com/article/2006810-overview. 14 Jan 2014. Accessed 01 Sep 2014.
  13. Thompson JF, Scolyer RA, Kefford RF. Melanoma, a management guide for GPs. Australian Family Physician. 2012 Jul;41(7):470-473. http://www.racgp.org.au/download/documents/AFP/2012/July/201207thompson.pdf. Accessed 20 Dec 2013.
  14. Wells GL. Melanoma. The Merck Manual. http://www.merckmanuals.com/professional/dermatologic_disorders/cancers_of_the_skin/melanoma.html. May 2013. Accessed 20 Dec 2013.
  15. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Journal of Clinical Oncology. 2012 Aug;30(23):2912-2917. http://jco.ascopubs.org/content/30/23/2912.full.pdf+html. Accessed 20 Dec 2013. PMID: 22778321
  16. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v126-v132. https://annonc.oxfordjournals.org/content/26/suppl_5/v126.full.pdf. PMID: 26314774
  17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma. Version 2.2016. NCCN website. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. 2016.
  18. National Institute for Health and Care Excellence (NICE). Melanoma: assessment and management. NICE website. https://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-1837271430853. 2015.
  19. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472–492. doi: 10.3322/caac.21409. PMID: 29028110
  20. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Dec;30(12):1884–1901. doi: 10.1093/annonc/mdz411. PMID: 31566661
  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Cutaneous melanoma. Version 1.2020. NCCN. https://www.nccn.org/. Dec 2019.
  22. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 Jan;80(1):208-250. doi:10.1016/j.jaad.2018.08.055. PMID: 30392755
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.